Business
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
SAN ANTONIO, June 26, 2025--bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/dc2ea773d760b719a2617dcbe05147a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mZf5h3QSbr0mjWPilfsTcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dc2ea773d760b719a2617dcbe05147a8","width":480,"height":201}},"lazy":false},{"type":"text","content":"SAN ANTONIO, June 26, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company’s recently issued U.S. Patent No. 12,305,171 and the notification of patent grant from the China National Intellectual Property Administration.","length":456,"tagName":"p"},{"type":"text","content":"The presentation at the 2025 RNA Therapeutics Conference, titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas," highlights a novel therapeutic approach that uses small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting two specific cell surface receptors, CD320 and LRP2. The data demonstrates that dual suppression of these proteins is highly effective in killing cancer cells while sparing normal cells, offering promising potential for the development of new RNA-based therapies. Research is underway to develop a topical treatment for cutaneous malignancies and neoplasms of the skin.","length":662,"tagName":"p"},{"type":"text","content":"RNA-based cancer therapeutics represent one of the fastest-growing segments within oncology, driven by the urgent need for more targeted and effective treatments. bioAffinity's approach, utilizing siRNAs to selectively silence cell surface proteins, holds substantial commercial promise due to its broad-spectrum effectiveness demonstrated across multiple tumor types including lung, breast, prostate, brain, and skin cancers. The potential to develop targeted therapies that could significantly enhance patient outcomes positions the Company favorably within this rapidly expanding market.","length":594,"tagName":"p"},{"type":"t...